ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TEK Tekcapital Plc

8.85
-0.15 (-1.67%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital Plc LSE:TEK London Ordinary Share GB00BKXGY798 ORD �0.004
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -1.67% 8.85 708,742 09:51:27
Bid Price Offer Price High Price Low Price Open Price
8.70 9.00 9.00 8.75 9.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Computer Programming Service USD 615k USD -12.75M USD -0.0715 -1.24 15.77M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:20:36 O 5,000 8.895 GBX

Tekcapital (TEK) Latest News (1)

Tekcapital (TEK) Discussions and Chat

Tekcapital (TEK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-28 16:20:368.905,000444.75O
2024-03-28 15:49:218.9010.09O
2024-03-28 15:46:268.9010,000889.80O
2024-03-28 15:45:378.9011410.15O
2024-03-28 15:40:319.001009.00O

Tekcapital (TEK) Top Chat Posts

Top Posts
Posted at 28/3/2024 08:20 by Tekcapital Daily Update
Tekcapital Plc is listed in the Computer Programming Service sector of the London Stock Exchange with ticker TEK. The last closing price for Tekcapital was 9p.
Tekcapital currently has 178,188,200 shares in issue. The market capitalisation of Tekcapital is £15,769,656.
Tekcapital has a price to earnings ratio (PE ratio) of -1.24.
This morning TEK shares opened at 9p
Posted at 19/2/2024 12:26 by retirementfund
Given that TEK share price is currently less than 50% of NAV and it appears that companies are clearly performing in a positive manner V NAV.

Having said that its not just about NAV for me Guident and Revive I suspect are worth significantly about current NAV but then if you look forward as to what they are going to be valued at the potential is truly staggering.

We saw negative comments at 6.5p I am sure we will see the same at much higher values than this each to their own in my view
Posted at 16/2/2024 08:14 by cheshire
Latest from the Oak Bloke- love the £1.46 target. :)TEK:Runnning my value model and plugging in the latest share prices for BELL, LUCY and SALT I see TEK's NAV remains at a 46.4% discount to market cap - even after a 130% YTD rise.How on earth you might ask? Well, the recent IPO from SALT has a lot to do with that. But the newsflow hasn't changed (much) from what I covered over the past months. SALT's chair gave a great presentation and SALT's CFO and CEO presented well with updates that several UK supermarkets are in discussions, but the fact and market potential of SALT is no different than pre-prospectus. It heartens me that TEK is making progress even when market sentiment is adverse. It proves that stock market eventually is a weighing machine, and if you have a conviction then do not panic and sell. Recurring 30 tonne orders of Microsalt from a global food business (cough Pepsi), and US supermarket stockists far larger than Sainsburys (CVS has 8,500 vs Sainsbury has 1,500) got weighed eventually.But interesting to note, too, that you can STILL buy SALT by buying TEK (who own a large chunk of SALT) at a discount. A very decent 16.66% discount.Not forgetting that it's a 16.66% discount plus you get 91% of Guident, 7% of BELL, 40% LUCY and 100% of ReVive all for free.Why free? Well 15p covers just 83% of the value of the Microsalt shares since TEK own 76% of SALT.I see no reason other than it has not been IPO'd why Guident is worth any less than SALT. I set out the known newsflow for Guident in this article. There are millions of lives lost each year to excess of salt, but one day soon billions of robots and drones needing guiden(t)ce. Even before science fiction becomes fact, Autonomous Vehicles (AVs) are already emerging rapidly for mass transit.Meanwhile for LUCY the addressable market size is $148bn and forecast to grow to $250bn by 2030. Deals with Nautica, Reebok and Eddie Bauer in 2024 make this an exciting pick despite the past poor performance while it got going. Their latest Q4 quarterly update is imminent and my last view on LUCY and my forecasts you can read in this article.Lucyd "are easily the best" is the conclusion in this video.ReVive meanwhile is a concept product which could further revolutionise transport range anxiety and particularly EVs, but PHEVs and HEVs too. Think about regenerative braking and how that has changed the world. It is now commonplace and in fact in 2024 you'd have to go really downmarket to find a car without regen braking or "start/stop" as it's commonly called. So what about generating power over the bumps in the road? ReVive claims a 5-10 mile range extension to an EV and is the sort of business which could be licenced to OEMs to draw in a revenue stream.Which leaves BELL, now funded, with an established market-leading pair of products for oxygen therapy which have been optimised to lower costs for higher margins, and an order book of 6,500 units and growing where they tick certain redemption codes which makes them attractive to equipment distributors to the point where BELL are the only game in town from some vendors.And that still leaves TEK's research business, and future forays as it perhaps looks to its 6th venture now three of its five businesses are listed.I have maintained a potential upside of £1.56 per share is possible over the next two years. TEK's share price, overall, would need to grow about 5.5 times to get there. That's because I see 5 businesses with USPs serving 5 enormous addressable markets.But another way to look at this is simply this.If BELL can return to its prior highwater price (£1.46 a share), if LUCY the same $7.50 a share, if ReVive can achieve 60% of the estimated $125m target value, if Guident were valued in an IPO and beyond in 2 years at 5X its NAV today, and if SALT tripled from here in the next 2 years to £2.85 a share, then you arrive at £1.55 per TEK share.Is it quite so impossible from that perspective? BELL has advanced far further than when it was at that previous high, and LUCY the same and is regularly being compared to - and in comparison videos beating global brands like Ray-Ban, Amazon and Bose. I guess for LUCY it depends whether you believe in the wisdom of crowds and the consumer, plus driving towards cash generation. ReVive is a unknown quantity but the increasing volumes of vehicles and tangibility of range anxiety isn't. Guident at 5X is no more fanciful than SALT at 5X (hint: SALT is half way there already). 5X could be far too low for a technology that puts humans in the loop in a rapidly arriving AI/Robotics world.How TEK could arrive at £1.56What if it doesn't? I am not saying it's guaranteed - it's an upside forecast. But at today's 15p a share, the risk/reward of TEK remains such that if even 1 out of the 5 succeed in a meaningful way the pay off could be several times today's share price. All five might succeed is my point.This is not adviceOakThanks for reading The Oak Bloke's Substack! Subscribe for free to receive new posts and support my work.
Posted at 08/2/2024 18:42 by 888icb
Article in this week IC just released:
SMALL COMPANIES
MicroSalt IPO highlights the value in Tekcapital
The stake in one of its portfolio companies is now worth more than its own market value
Simon Thompson

MicroSalt has market capitalisation of £18.5mn at listing price
Tekcapital retains 77 per cent stake and convertible loan notes
Tekcapital spot NAV more than double its current share price
MicroSalt (SALT:51.5p), a company that produces low-sodium salt, has raised £3.1mn, at 43p, in an Aim initial public offering (IPO). It’s less than initially planned, but in a moribund market for new listings, it is one of the few IPOs to get off the ground (‘Will MicroSalt whet investors’ appetite?’, 3 October 2023).

MicroSalt’s patented solution dissolves much faster on the tongue, so delivers the same sense of saltiness as traditional salt, but uses half the amount of sodium, a major contributor to hypertension and heart disease. The company has created a consumer brand of potato crisps, Salt Me!, which are now sold across 400 retail stores in the US, and has launched its MicroSalt shakers in 450 stores in the US as well as on Amazon in both the UK and US.

Moreover, the company has delivered its first commercial-volume order for a Fortune 500 retailer, which will use the solution for its own branded nuts to be sold across an initial 800 stores. Multiple multi-national companies are currently testing the product and are in price negotiations ahead of placing orders.

In the first half of 2023, MicroSalt reported a pre-tax loss of £1.7mn on revenue of £0.3mn, so it’s the potential to scale up sales rapidly that whets the appetite of investors. Given the obvious health benefits of the patented product, it’s not going to take that many deals with large fast-moving consumer goods (FMCG) customers to ramp up revenue and turn a business with a relatively fixed cost base profitable. MicroSalt looks to have a winning formula.

The IPO is also positive for Aim investment company Tekcapital (TEK:10.25p), which holds 33.3mn shares (77.3 per cent stake) in MicroSalt worth £17.1mn, and $2.6mn (£2mn) of convertible loan notes repayable in December 2025. Tekcapital’s investment in MicroSalt is worth more than its own market capitalisation of £18.3mn.
Deep share price discount to sum-of-the-parts valuation
In addition, Tekcapital has listed investments in Innovative Eyewear (US:LUCY), the US operating subsidiary of Lucyd, the first company to deliver prescription glasses with Bluetooth technology, and Aim-traded respiratory medical device company Belluscura (BELL). The holdings are worth £1.7mn (1p) and £2.1mn (1.2p), respectively, and are in the price for free.

The same is true of the company’s $18.3mn (8.1p) investment in Guident, a developer of remote monitoring and control centre (RMCC) software that improves the safety of autonomous vehicles and delivery robots.

Guident has signed software as a service (SaaS) agreements with European partners to provide its RMCC software for fixed-route electric bus services, having delivered its first remote monitoring and control services order to Jacksonville Transportation Authority in Florida. The company has also been awarded funding from Space Florida for a ground breaking project under the Florida-Israel Innovation Partnership programme.

Tekcapital's portfolio fair value estimate at 1 February 2024
Portfolio company Carrying value 30 June 2023 Estimated carrying value 1 February 2024 Value per share
Guident $18.3mn $18.3mn 8.1p
Innovative Eyewear $4.6mn $2.2mn 1.0p
Microsalt $17.1mn $21.8mn 9.6p
Belluscura $6.3mn $2.7mn 1.2p
Smart Food Tek $0.0mn $0.0mn 0.0p
Guident convertible loan notes $1.0mn $1.0mn 0.4p
MicroSalt convertible loan notes $1.5mn $2.6mn 1.2p
Portfolio fair value $48.6mn 21.6p
Net current assets (adjusted for second half operating costs) $1.0mn 0.4p
Intangible assets $0.3mn 0.1p
Total NAV $49.9mn 22.1p
Source: Tekcapital's 2023 interim accounts and London Stock Exchange RNS. The company reports in US dollars. Belluscura current valuation based on latest share price of 20p a share and holding of 10.6mn shares. Innovative Eyewear valuation based on stock price of $0.43 and holding of 5.19mn shares. MicroSalt valuation based on share price of 51.5p and holdings of 33.3mn shares. Guident valuation as reported in Tekcapital's 2023 interim accounts. Exchange rate used £1:$1.268.

Bearing this in mind, Guident has engaged a leading US investment bank to raise capital for expanding its RMCC business. At the bare minimum, it should provide investors with clarity that there is significant value in Tekcapital’s investment in the company. It’s worth noting, too, that Guident is conducting testing and appraisal of its proprietary regenerative shock absorber technology after completing successful paid-for proof-of-concept trials with a major tyre company. This could be a potentially lucrative recurring revenue stream, too.

So, although Tekcapital is the laggard in my 2022 Bargain Shares Portfolio, and the share price is below the 13p level in my last article, the 54 per cent share price discount to my spot NAV estimate of 22.1p is incredibly harsh. Buy.
Posted at 06/12/2023 09:49 by maytrees
Good morning

TEK share price still imho too low but at least some investors today appear optimistic given one or two recent very large buys.

For me, wait and see continues.
Posted at 30/8/2023 15:24 by lord loads of lolly
buywell3 - you claim "The chart of TEK IMO has been driven by that of BELL ---- hence buywell hopes and believes a recovery in the Belluscura share price chart --- which we are now seeing start to happen after the cash raise at 25p , could now drag the TEK share price chart back north. Note the current divergence caused by the surge in Belluscura SP".

I'd argue if you look at your charts closely, the conclusions you've drawn are debatable. Google charts indicate Belluscura's share price was around 136p in January 22, before dropping to 24p in June 23, then recovering slightly to 48p currently.

Meanwhile, TEK's share price was 34p in Jan 22, before dropping to around 11p in June 23, then slipping slightly further to its current 10.5p level since.

Whilst there was some correlation between BELL & TEK's share prices until June 23, BELL has since doubled in price, whilst TEK has done the exact opposite, falling slightly further. So there's now very little correlation and I don't think you can read too much into TEK's future share price direction by comparing it with BELL.
Posted at 30/8/2023 07:24 by buywell3
On the 17th Aug 2023 on the BELL thread buywell wrote:




17 August 2023


Portfolio Companies Update



Tekcapital Plc (AIM: TEK), the UK intellectual property investment group is pleased to provide a summary of latest developments across certain of its portfolio companies.



Belluscura



Belluscura plc ("Belluscura" AIM: BELL), announced on 16 August 2023 it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately US$15 million of potential revenue to Belluscura plc, as estimated by its management team. The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. Belluscura has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R.



Tekcapital owns 15,138,767 shares of Belluscura plc (11.16%).


-----------------------------------------------



buywell notes that Tekcapital still is a Major Shareholder in Belluscura , holding 15,138,767 shares of Belluscura plc (11.16%).


buywell hopes that Tekcapital can keep theses shares in Belluscura as they stage a recovery in share price based upon the coming surge of sales referred to in yesterdays Belluscura RNS and enhanced Telehealth software in the form of NOMAD its patented App , providing the necessary data for monitoring and control purposes by the remotely located patient Healthcare provider

The news imo underpinned what the Belluscura CFO recently said in video ie:

" Belluscura should be cash positive in the first half of 2024 "

The chart of TEK IMO has been driven by that of BELL ---- hence buywell hopes and believes a recovery in the Belluscura share price chart --- which we are now seeing start to happen after the cash raise at 25p , could now drag the TEK share price chart back north.





Note the current divergence caused by the surge in Belluscura SP






plus

As Belluscura starts to win market share from other existing oxygen concentrator providers , and sales into China and APAC begin in 2024

Belluscura with their disruptive patented technology will become a thorn in bigger sides

Sooner rather than later one of them will want to remove that thorn

dyor
Posted at 22/8/2023 09:58 by qsmeily456
So what....isn't going to boost the Tek share price especially when they have no cash and are diluting 2 to 3 times a year 🤣
Posted at 17/8/2023 06:59 by buywell3
Wrong

TEK have NOT sold any more Belluscura shares

plus

Advanced discussions with commercial partners including key players in the snack food industry are taking place in order to launch multiple products using Microsalt this year, with purchase orders anticipated in short order.


--------------------------------------------------------------


The importance of the Tekcapital shareholding in Belluscura should NOT be underestimated as BELL is currently the main driver of the TEK share price, and has been since mid 2021



Note the current divergence caused by the surge in Belluscura SP






plus

As Belluscura starts to win market share from other existing oxygen concentrator providers , and sales into China and APAC begin in 2024

Belluscura with their disruptive patented technology will become a thorn in bigger sides

Sooner rather than later one of them will want to remove that thorn
Posted at 17/8/2023 06:42 by buywell3
17 August 2023


Portfolio Companies Update



Tekcapital Plc (AIM: TEK), the UK intellectual property investment group is pleased to provide a summary of latest developments across certain of its portfolio companies.



Belluscura



Belluscura plc ("Belluscura" AIM: BELL), announced on 16 August 2023 it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately US$15 million of potential revenue to Belluscura plc, as estimated by its management team. The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. Belluscura has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R.



Tekcapital owns 15,138,767 shares of Belluscura plc (11.16%).


-----------------------------------------------



buywell notes that Tekcapital still is a Major Shareholder in Belluscura , holding 15,138,767 shares of Belluscura plc (11.16%).


buywell hopes that Tekcapital can keep theses shares in Belluscura as they stage a recovery in share price based upon the coming surge of sales referred to in yesterdays Belluscura RNS and enhanced Telehealth software in the form of NOMAD its patented App , providing the necessary data for monitoring and control purposes by the remotely located patient Healthcare provider

The news imo underpinned what the Belluscura CFO recently said in video ie:

" Belluscura should be cash positive in the first half of 2024 "

The chart of TEK IMO has been driven by that of BELL ---- hence buywell hopes and believes a recovery in the Belluscura share price chart --- which we are now seeing start to happen after the cash raise at 25p , could now drag the TEK share price chart back north.




dyor
Posted at 17/8/2023 06:39 by cheshire
Ignore the Smelly child, I now have him on filter, so he's been sent to the back of the class and I can no longer here his childish emoji muttering. The revival of the TEK share price will come IMHO.
Tekcapital share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock